Supernus Pharmaceuticals (SUPN) to Release Earnings on Tuesday

Key Points

• Supernus Pharmaceuticals is set to release its Q2 2025 earnings on August 5th, with analysts predicting earnings of $0.47 per share and revenue of $154.06 million.
• The company's stock is currently down 0.5%, trading at $33.41, with a 52-week range between $27.05 and $40.28.
• Recently, Wall Street Zen downgraded Supernus Pharmaceuticals from a "buy" to a "hold" rating, which indicates changing investor sentiment.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) will likely be releasing its Q2 2025 earnings data after the market closes on Tuesday, August 5th. Analysts expect the company to announce earnings of $0.47 per share and revenue of $154.06 million for the quarter.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock traded up $0.41 on Friday, hitting $35.51. 858,699 shares of the company traded hands, compared to its average volume of 590,504. The stock has a market capitalization of $1.99 billion, a P/E ratio of 31.99 and a beta of 0.70. Supernus Pharmaceuticals has a 52 week low of $27.05 and a 52 week high of $40.28. The business has a 50-day simple moving average of $32.57 and a 200 day simple moving average of $33.42.

Analyst Ratings Changes

SUPN has been the subject of a number of recent analyst reports. Cantor Fitzgerald raised shares of Supernus Pharmaceuticals from a "neutral" rating to an "overweight" rating and set a $42.00 target price for the company in a research note on Wednesday. Wall Street Zen downgraded Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Sunday, July 20th.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Millennium Management LLC increased its holdings in shares of Supernus Pharmaceuticals by 370.5% during the 1st quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company's stock valued at $4,695,000 after purchasing an additional 112,886 shares in the last quarter. Jane Street Group LLC purchased a new stake in Supernus Pharmaceuticals in the 1st quarter worth $3,641,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Supernus Pharmaceuticals by 7.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 107,789 shares of the specialty pharmaceutical company's stock worth $3,530,000 after acquiring an additional 7,769 shares in the last quarter. AQR Capital Management LLC increased its holdings in Supernus Pharmaceuticals by 35.2% in the 1st quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company's stock worth $2,791,000 after acquiring an additional 22,182 shares in the last quarter. Finally, Empowered Funds LLC increased its holdings in Supernus Pharmaceuticals by 16.0% in the 1st quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company's stock worth $1,573,000 after acquiring an additional 6,619 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.